TFW



November 16, 2006

Commissioner of Patents United States Patent and Trademark Office

Please find attached a reply to a USPTO Office communication dated 11/06/2006, regarding a USPTO Office Action Summary for the pending application:

No. 10/661,466, Applicants, Franco Vitaliano and Gordana Vitaliano; Russell S. Negin, Examiner, Art Unit 1631

Filed Pro Se

Franco Vitaliano

and

Gordana Vitaliano

4 Longfellow Place # 2105

Vitalian

Boston MA 02114 USA

Tel 617 742 4422

Fax 617 248 8886

francov@exqor.com





PATENT APPLICATION No. 10/661,466 Applicants: Franco Vitaliano and Gordana Vitaliano Response To Detailed Action Comments of 9/22/06 November 16, 2006, FedEx Air bill # 858896775091

To: USPTO
Art Unit 1631

Response To Detailed Action Comments, Date Mailed: 9/22/2006

A. Re the USPTO rejections per 35 U.S.C.112 of claims 23, 64, and 65, the claims are herein amended to resolve the ambiguity.

B.1. The USPTO has issued rejections per 35 U.S.C.101 of claims 1-16, 19-30, 35, 36, 41, 44, 46-49, 51-63, and 66-68, because, "In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter....", and,

B.2. The USPTO has issued rejections per 35 U.S.C.102 (b) of claims 1-16, 19-30, 35, 36, 41, 44, 46-49, 51-58, 62-63, and 66-68 for being anticipated by Gelderblom [AIDS, 1991, Volume 5, pages 617-637] which describes a naturally occurring human immunodeficiency virus (HIV), and,

B.3.The USPTO has issued rejections per 35 U.S.C.102 (b) of claims 1-16, 19-30, 35, 36, 41, 44, 46-49, 51-58, 62-63, and 66-68 for being anticipated by Stewart et al. [Current Topics is (sic) Microbiology and Immunology, 1995, volume 199, pages 25-38] which describes a naturally occurring adenovirus.

To briefly summarize, the USPTO asserts that naturally occurring HIV and a naturally occurring adenovirus as cited above in B.2 and B.3 share some structural and functional similarities with natural clathrin protein. The instant invention utilizes clathrin. The USPTO therefore says B.2 and B.3 anticipate the instant invention, which is a bio-based platform that features novelty and utility in quantum information processing.

The inventors of the instant invention dispute the USPTO's rejection of claims listed in A.1, 2, and 3, because, in fact, the listed claims relate to <u>non-naturally</u> occurring systems and are the result of the hand of man. For example, the terms "purified", and "bio-engineered," and their obvious synonyms like "man-made" and "non-naturally